Background:
Obesity, type 2 diabetes mellitus (T2D) and unhealthy blood lipid profile are strongly associated with the risk of developing cardiovascular disease (CVD). We examined whether blood lipid changes with short term administration of the weight lowering drug, sibutramine and lifestyle modification in obese and overweight high-risk patients was associated with T2D status at screening.
Methods:
The Sibutramine Cardiovascular OUTcomes (SCOUT) trial included obese and overweight patients at increased risk of cardiovascular events. All patients received guidance on diet and exercise plus once-daily 10mg sibutramine during the 6-week, single blind lead-in period. Multivariable regression models were used to investigate factors associated with changes in lipid levels during the first four weeks of treatment.
Results:
A total of 10 742 patients received at least one dose of sibutramine during the 6-week lead-in period of SCOUT. After four weeks, patients experienced mean reductions in low density lipoprotein (LDL-C) 0.19mmol/L, high density lipoprotein (HDL-C) 0.019mmol/L, very low density lipoprotein (VLDL-C) 0.08mmol/L, total cholesterol (TC) 0.31mmol/L and triglycerides 0.24mmol/L (p<0.0001 for each). Four week changes in LDL-C, HDL-C and total cholesterol for patients without vs. with T2D were: LDL-C:-0.25mmol/L vs. -0.18mmol/L, P=0.0004; HDL-C: -0.03mmol/L vs. -0.02mmol/L, P=0.0014; total cholesterol: -0.37mmol/l vs. -0.29mmol/l, P=0.0009. Multivariable regression analysis showed that similar decreases in body mass index (BMI) affected lipid changes differently according to diabetes status. A 1kg/m2 decrease in BMI in patients with T2D was associated with -0.09mmol/L in LDL-C (P<0.0001) and -0.01mmol/L in HDL-C (P=0.0001) but larger changes of -0.16mmol/L LDL-C and -0.03 mmol/L in HDL-C (P<0.0001 for both) in patients without T2D.
Conclusion:
Short term weight management with sibutramine therapy in obese or overweight high-risk patients induced significant mean reductions for all lipids. Those without T2D benefited most. Patients with hyperlipidaemia and the less obese patients also had greater falls in LDL-C and TC during weight loss.The trial is registered at ClinicalTrial.gov number: NCT00234832.

Further information:

Article source

Related posts:

1. Waist circumference cut-off values for the prediction of cardiovascular risk factors clustering in Chinese school-aged children: a cross-sectional study
2. Certain obese people are not at high risk of heart disease, diabetes
3. Medicine To Lower Blood Pressure Significantly Decreases Risk For Cardiovascular Disease, Stroke
4. The use of LeptiCore in reducing fat gain and managing weight loss in patients with metabolic syndrome
5. Gestational weight gain and risk of gestational diabetes mellitus.